In context
NNZ-2591 was examined in an open-label phase 2 study in children with Phelan-McDermid syndrome. Safety and drug exposure were primary outcomes; symptom assessments were secondary. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Without a randomised control group, improvement from baseline cannot reliably separate drug effects from expectation, natural variation or other influences.
How to interpret this evidence
Without a randomised control group, improvement from baseline cannot reliably separate drug effects from expectation, natural variation or other influences. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.